Introduction
Obstructive sleep apnoea (OSA) is a sleep-related 
Summary
There are multiple lines of evidence of a strong link between obstructive sleep apnoea and heart failure. First, obstructive sleep apnoea is associated with cardiovascular risk factors (hypertension and diabetes) and cardiovascular diseases (coronary artery disease, atrial fibrillation) which predispose to the development of heart failure. Second, obstructive sleep apnoea per se is associated with changes in cardiac structure and function. Third, the presence of obstructive sleep apnoea is related to an increased incidence of heart failure. Fourth, in patients with established heart failure with reduced ejection fraction (HFrEF), the presence of obstructive sleep apnoea is associated with worse outcomes. And fifth, mechanistic proof-of-concept studies have shown that treatment with continuous positive airway pressure (CPAP) not only successfully treats the obstructive sleep apnoea but also has the potential to reverse or at least to attenuate cardiac dysfunction in subjects with obstructive sleep apnoea without heart failure, as well as in patients with HFrEF and obstructive sleep apnoea. However, there are no randomised studies showing that treatment of obstructive sleep apnoea with CPAP improves clinical outcomes in patients with heart failure. In the present review, we summarise the current knowledge on the role of obstructive sleep apnoea as a risk factor predisposing to the development of heart failure, its role in patients with heart failure, the effects of CPAP on cardiac function in patients with and without heart failure, and the potential role of obstructive sleep apnoea as a disease modifier and therapeutic target in patients with heart failure.
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ity, increased daytime sleepiness and reduced quality of life [2] . Apart from the problem of daytime sleepiness and its potentially deleterious consequences, there is now a growing body of evidence suggesting an association between the presence and severity of OSA and cardiovascular diseases, in particular heart failure [1, 3, 4] . In this review, we provide a summary and critical discussion of the available evidence on the role of OSA as a risk factor predisposing to the development of cardiac dysfunction and heart failure, the importance of concomitant OSA in patients with heart failure, the effects of continuous positive airway pressure (CPAP) on cardiac function in patients with and without heart failure, and the potential role of OSA as a disease modifier and therapeutic target in patients with heart failure.
Definition and prevalence of obstructive sleep apnoea
The diagnosis of OSA is based on the apnoea-hypopnoea index (AHI) -the number of apnoeas and hypopnoeas per hour of sleep -which is assessed in a sleep study (polysomnography or polygraphy). An apnoea is defined as absence of airflow (reduction to less than 10% of baseline for ≥10 seconds), and a hypopnoea is defined as a reduction in airflow by ≥30% of baseline for ≥10 seconds and accompanied by a ≥3% decrease in oxygen saturation or an arousal [5] . The apnoea or hypo pnoea is obstructive if any of the following criteria are fulfilled: (a) snoring during the event, (b) increased inspiratory flattening of the nasal pressure waveform, (c) associated paradoxical motion of the chest and abdominal respiratory inductance plethysmography excursions [5] . Otherwise the event is central. The differentiation between obstructive and central events is particularly important in heart failure patients as it has impact on therapeutic considera- ) in men and 23% in women was found, which suggests that (asymptomatic) OSA is very common [7] . Thus, the relationship of OSA with heart failure is of interest for the majority of sleep and heart failure specialists, and even from a public health point of view.
Pathophysiology of the cardiovascular effects of obstructive sleep apnoea
The pathophysiology underlying the cardiovascular effects of OSA is complex and incompletely understood. There is also a biologically plausible link between OSA and insulin resistance [24] , and an association between the presence and severity of OSA and the prevalence [7, 25] and incidence [25, 26] However, this is in contrast to a previous randomised sham CPAP-controlled study with a longer treatment duration (3 months) in patients with type 2 diabetes mellitus and newly diagnosed OSA, which showed no effect of CPAP on glycosylated haemoglobin and insu- hyper tension, and the lack of control groups in several studies assessing the effect of CPAP on cardiac function. Nonetheless, these studies led to the concept that OSA per se is associated with changes in cardiac structure and function that may predispose to the development of heart failure and of disease progression in patients with established heart failure. Obstructive sleep apnoea and heart failure epidemiology OSA has been found to be associated with an increased prevalence and incidence of heart failure. In a crosssectional study (6424 subjects, median AHI 4.4 h 
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Pathophysiological concept of sleepdisordered breathing in heart failure
When discussing the role of sleep-disordered breathing in heart failure patients, it is of utmost importance to differentiate between OSA and central sleep apnoea, although both forms of sleep-disordered breathing can occur in the same patient. It is though that OSA is either a coexisting entity, which may have contributed to the occurrence of heart failure as discussed above, and which may adversely influence the clinical course of heart failure as discussed later, or that OSA occurs or worsens due to a so-called nocturnal rostral fluid shift:
swelling of the neck due to nocturnal fluid redistribution in patients with oedema [81, 82] . In the following paragraphs, the role of OSA is discussed as a disease modifier and potential therapeutic target in heart failure. Central sleep apnoea is not the topic of this review, but is briefly discussed to put the data on OSA into context. Central sleep apnoea is most likely an epiphenomenon of advanced heart failure and a marker of the severity of heart failure. For example, the severity of central sleep apnoea expressed as AHI is correlated with higher B-type natriuretic peptide levels and higher pulmonary capillary wedge pressure in HFrEF.
Although CPAP has been shown to improve AHI, mini- Heart failure with reduced ejection fraction and obstructive seep apnoea 
Summary and conclusions
There is good evidence for a causal link between OSA and cardiovascular risk factors, cardiac dysfunction, and cardiac diseases predisposing to heart failure including CAD and atrial fibrillation. OSA is associated with the major risk factors hypertension and diabetes, but may also directly contribute to adverse changes in cardiac structure and function, the occurrence and/or progression of CAD, and the incidence of atrial fibrillation. By these mechanisms, OSA may contribute to HFrEF or HFpEF, probably depending on the predominant mechanism, i.e., HFrEF in a CAD-dominant phenotype, and HFpEF in a phenotype with predominant hypertensive heart disease / atrial fibrillation. This hypothesis is schematically depicted in figure 2. In small prospective studies with surrogate endpoints, promising data on the effect of CPAP in HFrEF have been obtained. However, randomised studies with clearly defined study populations and clinical endpoints will be required to define to role of OSA, not only as a risk marker but also as a therapeutic target in heart failure patients. In the meantime, an indication for CPAP in heart failure and OSA exists only for patients with OSA-related symptoms of daytime sleepiness, where improvement of symptoms can be expected.
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